Oligomers of mutant glial fibrillary acidic protein (GFAP) Inhibit the proteasome system in alexander disease astrocytes, and the small heat shock protein αB-crystallin reverses the inhibition. by Tang,  G. et al.
Durham Research Online
Deposited in DRO:
20 December 2017
Version of attached ﬁle:
Published Version
Peer-review status of attached ﬁle:
Peer-reviewed
Citation for published item:
Tang, G. and Perng, M.D. and Wilk, S. and Quinlan, R. and Goldman, J.E. (2010) 'Oligomers of mutant glial
ﬁbrillary acidic protein (GFAP) Inhibit the proteasome system in alexander disease astrocytes, and the small
heat shock protein B-crystallin reverses the inhibition.', Journal of biological chemistry., 285 (14). pp.
10527-10537.
Further information on publisher's website:
https://doi.org/10.1074/jbc.M109.067975
Publisher's copyright statement:
This research was originally published in The Journal of Biological Chemistry. Guomei Tang, Ming D. Perng, Sherwin
Wilk, Roy Quinlan and James E. Goldman. Oligomers of Mutant Glial Fibrillary Acidic Protein (GFAP) Inhibit the
Proteasome System in Alexander Disease Astrocytes, and the Small Heat Shock Protein B-Crystallin Reverses the
Inhibition. The Journal of Biological Chemistry. 2010. 285: 10527-10537. c© the American Society for Biochemistry and
Molecular Biology
Use policy
The full-text may be used and/or reproduced, and given to third parties in any format or medium, without prior permission or charge, for
personal research or study, educational, or not-for-proﬁt purposes provided that:
• a full bibliographic reference is made to the original source
• a link is made to the metadata record in DRO
• the full-text is not changed in any way
The full-text must not be sold in any format or medium without the formal permission of the copyright holders.
Please consult the full DRO policy for further details.
Durham University Library, Stockton Road, Durham DH1 3LY, United Kingdom
Tel : +44 (0)191 334 3042 | Fax : +44 (0)191 334 2971
http://dro.dur.ac.uk
Oligomers of Mutant Glial Fibrillary Acidic Protein (GFAP)
Inhibit the Proteasome System in Alexander Disease
Astrocytes, and the Small Heat Shock Protein B-Crystallin
Reverses the Inhibition*
Received for publication, September 22, 2009, and in revised form, January 19, 2010 Published, JBC Papers in Press, January 28, 2010, DOI 10.1074/jbc.M109.067975
Guomei Tang‡, Ming D. Perng§, Sherwin Wilk¶, Roy Quinlan§, and James E. Goldman‡1
From the ‡Department of Pathology and Cell Biology, Columbia University, New York, New York 10032, the §School of Biological
andMedical Science, University of Durham, DurhamDH1 3LE, United Kingdom, and the ¶Department of Pharmacology and
Biological Chemistry, Mount Sinai School of Medicine, New York, New York 10029
The accumulation of the intermediate filament protein, glial
fibrillary acidic protein (GFAP), in astrocytes of Alexander dis-
ease (AxD) impairs proteasome function in astrocytes. We have
explored the molecular mechanism that underlies the protea-
some inhibition.We find that both assembled and unassembled
wild type (wt) and R239C mutant GFAP protein interacts with
the 20 S proteasome complex and that the R239CAxDmutation
does not interfere with this interaction. However, the R239C
GFAP accumulates to higher levels and forms more protein
aggregates than wt protein. These aggregates bind components
of the ubiquitin-proteasome system and, thus, may deplete the
cytosolic stores of these proteins. We also find that the R239C
GFAPhas a greater inhibitory effect on proteasome system than
wt GFAP. Using a ubiquitin-independent degradation assay in
vitro, we observed that the proteasome cannot efficiently
degrade unassembled R239C GFAP, and the interaction of
R239C GFAP with proteasomes actually inhibits proteasomal
protease activity. The small heat shock protein, B-crystallin,
which accumulates massively in AxD astrocytes, reverses the
inhibitory effects of R239C GFAP on proteasome activity and
promotes degradation of themutant GFAP, apparently by shift-
ing the size of the mutant protein from larger oligomers to
smaller oligomers and monomers. These observations suggest
that oligomeric forms of GFAP are particularly effective at
inhibiting proteasome activity.
Alexander disease (AxD)2 is a rare but fatal disease of the
central nervous system characterized by the presence in astro-
cytes of Rosenthal fibers, cytoplasmic protein aggregates that
contain the intermediate filament protein, glial fibrillary acidic
protein (GFAP), ubiquitinated proteins, and small heat shock
proteins (shsps) (1). Because of the loss of myelin and oligoden-
drocytes and a variable loss of neurons, AxD has been histori-
cally thought of as a leukodystrophy or neurodegenerative dis-
order. AxD is, however, a disease of astrocyte dysfunction, as
mutations in GFAP are found in the large majority of AxD
patients (2). All mutations detected so far are heterozygous
codingmutations, andmost cases of AxD disease arise through
de novo, dominant, GFAP mutations (2). Most of the AxD
mutations reside in the 1A, 2A, and 2B segments of the con-
served central rod domain of GFAP, but several are located in
the tail region (2). AlthoughGFAPmutationsmust underlie the
pathogenesis of AxD, the mechanisms by which GFAP muta-
tions are toxic have not been fully elucidated.
TheArg-239 residue is a “hot spot” forGFAPmutagenesis, as
substitutions at this arginine are the most frequent mutations
found in AxD and appear among different ethnic groups (2).
Our previouswork has concentrated on themost common sub-
stitution, R239C, and has demonstrated that overexpressing
GFAP, either wild type (wt) or the R239C mutant, leads to the
formation of intracellular protein aggregates (3–5). GFAP
accumulation also inhibited proteasome protease activity and
increased levels of ubiquitinated GFAP species (5). Although
overexpressingwtGFAPcan lead to intracellular protein aggre-
gates, the R239C mutation exacerbates GFAP accumulation
and aggregation and aggravates the effects of GFAP accumula-
tion in inducing intracellular stress responses and in inhibiting
proteasome activities (5).
In the present study we have explored the mechanisms that
underlie the impaired proteasome function by GFAP accumu-
lation. We asked if GFAP interacted with proteasomes in cells
and in vitro and further asked if this interaction resulted in
proteasome inhibition. Finally, we examined if B-crystallin, a
shsp and molecular chaperone, could reverse the GFAP-medi-
ated proteasome inhibition. Both assembled (10-nmwide poly-
mers) and unassembled (soluble at 80,000  g) GFAP protein,
both wild type and mutant, interact with the 20 S proteasome
complex. The unassembledGFAP includes amix ofmonomeric
and oligomeric forms. Compared with the wt GFAP, the unas-
sembled R239C GFAP showed a marked shift toward larger
oligomers. In addition, the unassembled R239C had a far
greater inhibitory effect on proteasome proteolytic activity in
vitro than did the wt GFAP. The addition of B-crystallin,
which accumulates massively in AxD astrocytes, reversed the
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inhibitory effects of the R239C GFAP on proteasome activity.
B-Crystallin also changed the oligomer-monomer distribu-
tion of the R239C GFAP to a point at which it appeared identi-
cal to that of the wt GFAP. Our observations direct a focus on
oligomeric forms of GFAP as effective proteasome inhibitors
and suggest mechanisms that underlie the proteasome inhibi-
tion in astrocytes of the AxD brain. In addition, because the
R239C GFAP aggregates could bind components of the ubiq-
uitin-proteasome system, they may deplete the cytosolic stores
of these proteins.
EXPERIMENTAL PROCEDURES
Reagents—Cell culturemedium (Dulbecco’smodified Eagle’s
medium) andmolecular biological reagentswere obtained from
Invitrogen and Qiagen. Primary antibodies included anti-
GFAP polyclonal antibody (pAb, DAKO), anti-GFAP mono-
clonal antibody (mAb), anti-B-crystallin pAb, anti-ubiquitin
mAb (Chemicon), anti-glyceraldehyde-3-phosphate dehydro-
genase mAb (Encor), and anti-20 S pAb (Biomol). The fluores-
cence-conjugated and horseradish peroxidase-conjugated sec-
ondary antibodies were from Chemicon and Amersham
Biosciences. Imidazole-HCl, EDTA, MG132, lactacystin,
camptothecin, anti-FLAG M2-agarose affinity gel and protein
G-Sepharose were from Sigma.
Brain Tissue—Tissues stored at80 °C from cerebral hemi-
spheric white matter of control subjects or AxD cases with dif-
ferent mutations were obtained postmortem. For immunohis-
tochemistry, the tissue was fixed in formalin and then
embedded in paraffin. All AxD cases were diagnosed based on
histopathological examination and confirmed by themolecular
genetic analysis for GFAP mutation. Controls included frozen
central nervous system tissue from two children, one with no
neurological disease (Control I) and one with Werdnig-Hoff-
man disease (non-AxD, non-leukodystrophy neurological dis-
ease without Rosenthal fibers) (Control II).
Cell Cultures and Transfection—cDNA clones encoding wt
GFAPorR239CmtGFAPwere inserted intoEGFP-C1expression
vector for expressing a GFP-GFAP fusion protein. To generate
permanent cell lines, U251 astrocytoma cells were transfected
with theGFAP-GFPplasmid using calciumphosphate. The trans-
fected cells were then cultured in Dulbecco’s modified Eagle’s
medium supplement with 10% fetal calf serum, antibiotics, and
500 g/ml G418. Clonal lines of stably transfected cells were iso-
lated and confirmed by fluorescence-activated cell sorter sorting
orWestern blot analysis. MG132 (10M) and lactacystin (10M)
were added to cultures at 24 h post-transfection and incubated for
a further 24 h, with DMSO as the vehicle control.
Immunoprecipitation and Western Blotting—For protein
extraction and fractionation, brain tissue or cells were lysed in
total cell lysis buffer (2% w/v SDS, 6.25%mMTris, pH 7.5, 5 mM
EDTA supplemented with a Roche Applied Science protease
inhibitor mixture tablet) for total protein or in fractional lysis
buffer to separate soluble and insoluble fraction. Briefly, cells or
brain tissues were recovered in S1 buffer (0.5% v/v Triton X, 2
mM Tris, 2 mM EDTA, and sucrose implemented with Com-
plete Mini Roche Applied Science protease inhibitor mixture).
After centrifugation for 20min at 15,000 rpm at 4 °C, the super-
natant was collected as the “soluble” fraction, and the pellet
(“insoluble” fraction) was recovered in S2 buffer (2%w/v SDS, 2
mM Tris, 2 mM EDTA). Protein concentration was determined
using a Bio-Rad protein assay kit according to the manufactur-
er’s instructions.
For immunoprecipitation, Cos7 cells were transiently trans-
fected with FLAG-tagged wt and R239C GFAP or vector only.
Immunoprecipitations were performed 48 h post-transfection.
Equal amounts of protein from whole cell extract soluble frac-
tions were diluted in immunoprecipitation lysis buffer (6) and
were incubated with anti-FLAGM2-agarose gel or anti-20 S
antibody and protein G-Sepharose overnight at 4 °C. Immuno-
precipitates were then separated by SDS-PAGE and subjected
to Western blotting.
Proteasome Activity Assay—Brain tissues and cells were
homogenized in ice-cold proteolysis buffer (10 mM Tris-HCl,
pH 7.2, 0.035% SDS, 5 mM MgCl2, 5 mM ATP, and 0.5 mM
dithiothreitol). The homogenates were centrifuged at 13,000
g for 10 min, and the resulting supernatant was incubated with
proteasome substrate II (S-II: benzyloxycarbonyl-Leu-Leu-
Glu-amidomethylcoumarin) or III (S-III: Suc-Leu-Leu-Val-
Tyr-amidomethylcoumarin) to detect the peptidylglutamyl
peptide hydrolase (PGPH) and chymotrypsin-like peptidase
activities, respectively. Fluorescence was monitored at 360-nm
excitation and 450-nm emission in a fluorescence plate reader
(Bio-Tek FL600).
Immunocytochemistry and Immunohistochemistry—Immu-
nostaining of cultured cells was performed at 48 h after trans-
fection as described before (4). A cytoskeleton buffer (PHEM
buffer: 100 mM Pipes, 2 mM EGTA, 1 mM MgCl2, 0.5% Triton
X-100, pH 6.8) was utilized to characterize the cytoskeleton.
Cells were visualized by a Zeiss LSM510 confocal microscope.
Immunohistochemistry was performed according to general
protocols. 10-m-thick consecutive sections were prepared.
Sections were blocked in Tris-buffered saline-Tween, 5% bovine
serumalbumin for1handsubsequently incubatedwithantibodies
against the 20Sproteasomecomplex (1:100),B-crystallin (1:100)
ubiquitin (1:100), and GFAP (1:200) overnight at 4 °C. Negative
control sectionswereheld inphosphate-buffered salineduring the
primary incubation. Sections were then incubated with horserad-
ish peroxidase-labeled secondary antibody 1 h at room tempera-
ture and developed with 3,3-diaminobenzidine.
In Vitro GFAP Assembly and Co-sedimentation Assay—Re-
combinant human wt and R239C GFAP were purified from
Escherichia coli BL21 (DE3) pLysS and assembled in vitro as
before (7). The assembled wt or R239C GFAP filaments were
incubated with purified 20 S proteasomes (8) at room temper-
ature for 1.5 h. Samples were then separated into pellet and
supernatant fractions by ultracentrifugation at 80,000  g for
30 min at 4 °C and assayed by Western blotting.
Statistical Analysis—Results are expressed as the mean 
S.D. Statistical analysis was performed using ANOVA. p 0.05
was considered statistically significant.
RESULTS
GFAP Aggregation Decreases Proteasome Activity and
Depletes Cytosolic Proteasomes—We first assessed the protea-
some protease activities in theU251 astrocytoma cell line stably
transfected with control, wt GFAP, and R239C GFAP expres-
AxDMutant GFAP Accumulation Inhibits Proteasome Function
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sion vectors. In comparing cells transfected with vector only
(used as control and set to 100% activity), the PGPHactivitywas
reduced in cells expressing wt GFAP (p  0.05) and further in
those expressing R239CGFAP (p 0.01), whereas the chymot-
rypsin-like peptidase activity showed a non-significant reduc-
tion in wt and amodest reduction in R239C cells (p 0.01, Fig.
1A). The decreased proteasome activity due to GFAP accumu-
lation was not caused by the loss or reduction of proteasome
complexes as the total amount of the 20 S complex remained
the same in the vector-transfected cells and the GFAP-express-
ing cells (Fig. 1B). However, we observed a shift of 20 S complex
from a Triton X-100-soluble fraction to the insoluble fraction
(Fig. 1C).
We detected significantly decreased PGPH and chymotryp-
sin-like protease activities in white matter from AxD patients
with the R239C, R416W, and R239H mutations (Fig. 1D),
although 20 S complex protein levels were at the same levels
or increased compared with that in white matter without
Rosenthal fibers from a non-AxD subject (Fig. 1E).
The 20 S proteasome complex has been reported to be as-
sociated with aggresomes, intracellular protein aggregates
formed by misfolded proteins (9). In the U251 cells, the GFAP
inclusions were labeled with anti-
bodies to the proteasomal 20 S com-
plex and to ubiquitin (Fig. 2A).
Many more of the cells expressing
the R239CGFAP showed inclusions
compared with cells expressing
wt GFAP (Fig. 2D). Treatment of
cells with proteasome inhibitors
increased GFAP levels and in-
creased the proportion of cells that
contained inclusions (Fig. 2, C and
D). When we examined sections
from the brains of AxD patients, we
found a similar distribution of
GFAP, the 20 S proteasome and
Rosenthal fibers (Fig. 2B). Because
this similar distribution can only
suggest, but cannot prove physical
interactions among these compo-
nents, we looked at cell and in vitro
systems (see below).
Associations between 20 S Protea-
some and Non-assembled GFAPs—
Based on the fact that proteasomes
associate with different types of
intermediate filaments, including
keratin, desmin, and vimentin (10,
11), we inferred that, as a type III
intermediate filament, GFAPs may
interact with 20 S proteasome com-
plexes, and the interaction of pro-
teasome complexes with the accu-
mulated GFAP might interrupt the
normal proteasome function. To
address this possibility, we per-
formed a series of co-immunopre-
cipitations in Cos7 cells transiently transfected with FLAG-
tagged wt or R239C GFAP. Because it has been reported that
some proteasomes are present in the Triton X-100-soluble
membrane and cytosolic fractions (12), we looked for GFAP-20
S complexes in the Triton X-100-soluble fractions of Cos7 cells
(Fig. 3A). Reciprocal co-immunoprecipitations using anti-20 S
antibodies and anti-FLAG antibodies revealed that both wt
and R239C GFAPs were present in complexes with 20 S pro-
teasomes. Protein A-Sepharose beads without anti-20 S anti-
bodies were used as a background control, as were non-
transfected Cos7 cells and Cos7 cells transfected with the
empty vector. Note that the polymerized GFAP intermediate
filaments were excluded from this assay, as they are part of
the Triton X-100-insoluble, cytoskeletal network, which is
also insoluble in immunoprecipitation buffer. However,
when we treated the cells first with a cytoskeleton buffer
(PHEM, containing 0.5% Triton X), which extracts soluble
proteins, double immunofluorescence examination showed
that proteasomes continued to associate with GFAP inclu-
sions even when soluble, cytoplasmic proteins were removed
(Fig. 3B), suggesting that some of the 20 S subunits associ-
ated with cytoskeletal GFAP.
FIGURE 1. GFAP accumulation decreases proteasome activity. A, proteasome proteolytic activity in U251
cells stably expressing EGFP vector (V), wt GFAP (wt), and R239C GFAP (mt) is shown. 48 h after plating, cells
were lysed, and the proteasome PGPH and chymotrypsin-like protease activities were analyzed by using the
fluorescent substrates S-II and S-III, respectively. Protease activities in cells expressing EGFP-C1 vector were set
to100%. The results are theaverage from five independent experiments. *,p0.05, **,p0.001, by two-tailed
ANOVA. B, shift of 20 S proteasome from soluble pool to insoluble pool in U251 cells stably expressingwt ormt
GFAP is shown. The U251 cells were harvested 48 h after plating at 80% confluency. Triton X-100 soluble (30
g), insoluble (10g), or total protein (15g)was analyzedbyWesternblottingwith ananti-20Santibodyand,
after stripping, with an anti-GFAP and finally with an anti-glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) antibody to normalize for loading. C, shown is quantitation of levels of 20 S in total, soluble, and
insoluble fractions of cell lysates fromU251 cells expressing EGFP-C1 vector (V), wt (WT), andmt GFAPs (mt). In
comparing cells transfectedwith vector only as control, protein levels of 20 S inwt ormtGFAP-expressing cells
were reducedmarkedly in the soluble fraction but enhanced significantly in the insoluble fraction. *, p 0.05,
**, p 0.001, by two-tailed ANOVA. D, shown is decreased proteasome proteolytic activity in AxD brain with
R239C, R239H, and R416W mutations. Protease activities in control subject I was set to 100%. Each result
represents a mean S.D. of five independent experiments. *, p 0.05, **, p 0.001, by two-tailed ANOVA.
E, shown is Western blotting analysis of 20 S proteasome in brains of AxD patients (control subject II not
included).
AxDMutant GFAP Accumulation Inhibits Proteasome Function
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20 S Proteasome Bind to Assembled GFAP Filaments in Vitro—
To determine whether GFAP intermediate filaments will asso-
ciate directly with proteasomes, we turned to in vitro analyses,
first using a co-sedimentation assay (7). Purified 20 S protea-
some complexes were incubated with in vitro assembled wt or
R239CGFAP filaments at aweight ratio of 1:1 orwithoutGFAP
(as a control) for 1.5 h. The samples were centrifuged at
80,000 g in 40% sucrose, washedwith assembly buffer and the
PHEM buffer, and finally resolved by SDS-PAGE. Nitrocellu-
lose blots were probed with an anti-20 S antibody and then
re-probed with an anti-GFAP antibody. The 20 S proteasomes
incubated without GFAP could not be recovered in the pellet
fraction (Fig. 3C). In contrast, when incubated with assembled
wt or R239CGFAP filaments, a fraction of the 20 S proteasomes
co-sedimented with the GFAP (Fig. 3C). This result revealed a
direct association between proteasomes and GFAP filaments.
Note that the R239C mutation apparently does not interfere
with this binding.
Both Soluble and Aggregated Forms of GFAP Inhibit Protea-
some Function—Our data above indicated a direct interaction
between GFAP and proteasome complexes, but we could not
discern if the interaction interrupts proteasome function. To
FIGURE 2. R239C GFAP aggregates recruit ubiquitin proteasome system components, and proteasome inhibitors regulate GFAP accumulation.
A, GFAP inclusions in R239Cmutant GFAP cells were labeled with antibodies to ubiquitin (upper) and the proteasomal 20 S complex (lower). U251 cells stably
expressingmutant GFAPwere treatedwith Triton X-containing cytoskeletal buffer and fixedwith 4%paraformaldehyde, thenwere immunostained for GFAP,
20 S, or ubiquitin. Merged images on the right show 20 S or ubiquitin in red, GFAP-GFP in green, and the overlap in yellow. Aggregates are indicated by arrows,
andnuclei are indicatedbyasterisks. Note that in eachpanel cellswithout aggregateswere included for control. After removal of soluble cytosolic protein,most
of theproteasomecomponents remain in cell nuclei.Scalebar, 10m.B, immunohistochemistryofbrain tissueof anAxDpatient andacontrol usingantibodies
againstGFAP, 20S, andubiquitin are shown.Hematoxylin andeosin stainingof theAxDbrain showedextensive, brightly eosinophilic Rosenthal fibers (arrows),
some ofwhich surround vessels (hematoxylin and eosin (H&E), 40). No Rosenthal fibers are present in control whitematter. GFAP immunostaining of control
white matter shows cells with typical, process-bearing, astrocyte morphology and many thin astrocyte processes, whereas in AxD, GFAP immunostains
highlight the Rosenthal fibers. Correlated with the GFAP immunostaining, the signal for both 20 S and ubiquitin was localized to Rosenthal fibers. V, blood
vessel; arrows, Rosenthal fibers. Scale bar, 100 m. C, effects are shown of proteasome inhibition on GFAP accumulation. U251 cells stably expressing vector
control (V), wt GFAP (WT), and R239C GFAP (mt) were incubated with mediumwith or without MG132 or lactacystin for 12 h. Total cell lysates were subjected
to SDS-PAGE andWestern blotting analysis with antibodies against GFAP and glyceraldehyde-3-phosphate dehydrogenase (GAPDH).D, shown is the percent-
ageof cellswith aggregates after exposure toproteasome inhibitors. Results are the averageS.D. from three independent experiments,with at least 400 cells
counted in each. A larger percentage of the R239C GFAP-expressing cells, compared with wt expressing cells, contained aggregates under all treatment
conditions. Different treatmentswere then comparedwithin thewtor R239CGFAPexpressinggroupusingDMSOas control. **, comparedwithDMSOcontrol,
by two-tailed ANOVA, p 0.001.
AxDMutant GFAP Accumulation Inhibits Proteasome Function
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address this possibility, we performed an in vitro ubiquitin-
independent proteasome degradation assay by examining the
activity of purified 20 S proteasomes in the presence of recom-
binant wt GFAP, R239CGFAP, orMG132, again using fluores-
cent substrates to monitor proteasomal protease activity. We
first examined how soluble wt and R239C GFAPs (separated
from pelleted, assembled wt and R239C GFAPs by centrifuga-
tion in 40% sucrose at 80,000  g as described above) affected
proteasome function. wt and R239CGFAPs were isolated from
the top layers and were incubated at identical concentrations
with purified 20 S proteasome for 30 min. We then added
fluorescent substrates and 30 min later analyzed the samples.
Compared with those incubated with substrates only, 20 S pro-
teasome complexes exposed to R239C GFAP showed a signifi-
cantly decreased activity. In contrast, wt GFAP showed less
inhibitory effects on 20 S proteasome activity (Fig. 3D). In the
positive control, MG132-treated proteasomes were almost
completely inhibited.
We also assessed the effect of assembled wt and R239C
GFAPs on 20 S proteasome activity. In vitro assembled wt or
R239C GFAP filaments were separated from soluble GFAP by
centrifugation and preincubated with purified 20 S proteasome
complexes. The fluorescent substrates were added to examine
proteasomal proteolytic activity. Compared with MG132-
treated samples and the negative control, the R239C GFAP fil-
aments exhibited a significant inhibitory effect on proteasomes,
whereas the wt GFAP filaments only slightly inhibited PGPH
protease activity (Fig. 3D). However, these inhibitory effects
were far less than those produced by non-assembledGFAP on a
weight/weight basis. This result suggested that the inhibition of
proteasomes by R239C GFAP might be predominantly attrib-
uted to soluble GFAPs.
FIGURE 3. 20 S proteasome associates with soluble and aggregated GFAPs. A, co-immunoprecipitation (IP) of 20 S proteasome and GFAP revealed
that both wt and R239C mutant GFAPs were present in complexes with 20 S proteasomes. Cos7 cells were transiently transfected with pcDNA3-FLAG
vector, vectors expressing wt, and R239C GFAP. Forty-eight hours after transfection, cells were harvested and lysed with 1 radioimmune precipitation
assay buffer. GFAP was immunoprecipitated with anti-FLAG M2-agarose affinity gel, and the 20 S proteasome complex was precipitated by protein
A-Sepharose beads conjugated with an anti-20 S antibody. C, untransfected cells; V, pcDNA3-FLAG vector-transfected cells; wt andmt, cells expressing
FLAG-tagged wt or mt GFAP; NC, protein A-Sepharose beads without GFAP and 20 S antibody. GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
B, 20 S proteasome associates with Triton-insoluble GFAP aggregates in U251 cells. U251 cells stably expressing wt or mt GFAPs were treated with Triton
X-containing cytoskeletal buffer and fixed with 4% paraformaldehyde and then examined for GFAP-GFP (green) and 20 S (red) fluorescence. GFAP
aggregates are indicated by arrows, and nuclei are indicated by asterisks. Scale bar, 10 m. C, 20 S proteasome associates with insoluble, filamentous
GFAPs in vitro. Both wt and R239C GFAP were assembled in vitro as described (7) with or without purified 20 S proteasomes. Without GFAP (left panel),
the 20 S proteasomes remain in the soluble (S) fraction, and none appeared in the pellet fraction (P). C is a control lane loaded with 20 S proteasome
subunits. With reassembled wt and R239C GFAP (middle and right panels), the 20 S subunits were recovered in the pellet fraction (P). Western blots were
performed with both anti-GFAP and anti-20 S antibodies. D, both soluble and aggregated forms of GFAP inhibit proteasome function. Purified protea-
somes were incubated without (PS only) or with soluble non-assembled (S) or assembled (P) wt and R239C (RC) GFAPs. One hundred g of soluble (S) or
assembled (P) GFAPs were incubated with proteasome (100 g) for 30 min in a total volume of 200 l. Proteasome activity was then analyzed using
fluorescent substrates (100 M) with a fluorescence microplate reader at an excitation wavelength of 360 nm and an emission wavelength of 440 nm.
Comparedwith those exposed to substrates only (PS only), both solublemt GFAP (RC/S) and pellet R239CGFAP (RC/P) significantly inhibited proteasome
PGPH and chymotrypsin-like proteolytic activities. **, compared with PS only, by two-tailed ANOVA, p  0.001.
AxDMutant GFAP Accumulation Inhibits Proteasome Function
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In all of the proteasome inhibition experiments we kept the
GFAP concentration between 0.25 mg/ml (50g/200l) and 1
mg/ml (200 g/200 l), which we believe is within the physio-
logical range given the following estimates. GFAP represents
about 1.0% of total brain protein in the adult rat (13). If brain is
11% protein and 9% protein by wet weight in adult rat and
human, respectively (14), or about 90 mg/ml, the GFAP con-
centration would be 0.90 mg/ml. If astrocytes take up about
10% of brain volume (15) and as GFAP is only found in astro-
cytes, the GFAP concentration in astrocytes is in the order of
9.0 mg/ml (may be higher in white matter astrocytes, as their
GFAP content is greater than that of gray matter astrocytes).
The central nervous system in patients with AxD contains
markedly increased amounts of GFAP, up by at least 10-fold,
thus, giving a GFAP concentration of 90 mg/ml. The soluble
GFAP is operationally defined asmaterial that does not pellet at
a specified g force and in a normal brain represents a small
fraction of the total GFAP. Thus, in the adult rat brain after
Triton X-100 solubilization and centrifugation at 180,000 g,
about 0.8% of the total GFAP appears in the soluble fraction
(13). Thus, the solubleGFAP concentration in astrocyteswould
be around 0.72 mg/ml.
R239C GFAP Inhibits Protea-
some Activity in a Non-competitive
Manner—To understand how non-
assembled GFAPs inhibit 20 S pro-
teasome activity, we varied the con-
centration of fluorogenic substrates
at a constant concentration of wt or
R239CGFAP andmeasured proteo-
lytic activities. Purified proteasomes
were incubatedwith soluble or poly-
merized wt and R239C GFAPs, and
20 min later, proteasome substrates
II or III were added. For protea-
somes unexposed to GFAPs, as a
control, the degradation of protea-
some substrates increased with
increasing substrate concentration
and reached a maximum activity at
a concentration of 100 M. With a
further increase in substrate con-
centration, the proteasome activity
decreased slightly (Fig. 4A), sug-
gesting that increasing substrate
concentration beyond a threshold
may inhibit proteasome proteolytic
activities. In the range of 100 M
substrate concentration, the activity
of 20 S proteasome exposed to fila-
mentous or unassembled wt GFAP
increased with increasing substrate
concentrations (Fig. 4A), similarly
to the activity without GFAP, al-
though there appeared to be some
small inhibition at higher SII sub-
strate levels. These data indicate
that the proteasomal inhibition that
we observed beforewas not a false positive result from substrate
binding and substrate sequestration. Thus, GFAP seems to
inhibit the proteasome activity via an interaction with the pro-
teasome rather than by binding substrate peptide. The
R239C GFAP produced a significant inhibition of protea-
some activity, with the unassembled (soluble) GFAP exhib-
iting the greatest effect (Fig. 4A). Interestingly, proteasome
activity did not continue to increase with increasing concen-
trations of substrate, suggesting that the interaction between
soluble R239C GFAP and proteasomes produced a non-
competitive inhibition of proteasome activity.
Next, we assayed the PGPH and chymotrypsin-like protease
activities at different GFAP concentrations (50, 100,150, 200
g/200-l total reaction volume), with the fluorescent peptide
substrate concentration fixed at 100 M. The R239C GFAP
inhibited PGPH and chymotrypsin-like activity more than the
wt GFAP at all GFAP concentrations (Fig. 4B). For example, at
the 100 g/200 l, the R239C GFAP inhibited almost 50% of
proteasome activity, whereas the wt inhibited only 10% of total
activity; at 200 g/200 l, the R239C GFAP produced a 90%
percent inhibition, whereas thewtGFAPwas far less inhibitory.
FIGURE 4. R239C GFAP inhibited proteasome activity in a non-competitive manner. A, R239C mt GFAPs
inhibited proteasome activity in a non-competitive manner. Purified proteasomes (100 g) were incubated
without (PS only) or with soluble (S) or polymerized (P) wt and R239C (RC) GFAPs (100g). 20min later protea-
some substrate II or III was added at different concentrations (25, 50, 75, 100, 125 M), and proteasome pro-
teolytic activity was analyzed. B, shown are PGPH and chymotrypsin-like protease activities at different GFAP
concentrations (50, 100, 150, 200g/200l), with the fluorescent peptide substrate concentration fixed at 100
M. Compared with 20 S only, *, p  0.05; **, p  0.001, by two-tailed ANOVA. C, shown is proteasome
degradation of wt and R239CGFAP. Soluble wt and R239CGFAPswere incubatedwith or without 20 S protea-
somal subunits andwith orwithoutMG132, electrophoresed on SDS gels, and immunoblottedwith anti-GFAP
antibody. This experiment was repeated three times with similar results.
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MG132, as a positive control, blocked the protease activity
markedly (Fig. 4B).
SolublewtGFAP, butNot R239CGFAP, Is PartiallyDegraded
by the 20 S Proteasome—We then asked whether the wt and the
R239C GFAPs could be efficiently degraded by 20 S protea-
somes via a ubiquitin-independent manner in vitro. Soluble wt
and R239C GFAPs were incubated with 20 S proteasomes, and
products were analyzed byWestern blotting. After exposure to
20 S proteasomes, a fraction of the wt GFAP was broken down
into smaller fragments (Fig. 4C). In contrast, the R239C GFAP
was degraded only minimally (Fig. 4C). In the presence of
MG132, as a positive control, neither wt nor R239C GFAP was
degraded. Thus, although both wt and R239C GFAP can inter-
act with proteasome 20 S complexes, the R239C GFAP cannot
be efficiently degraded.
The Molecular Chaperone B-Crystallin Restores Protea-
some Proteolytic Activity That Was Reduced by R239C GFAP—
We then asked if B-crystallin could rescue proteasome func-
tion from theR239CGFAP toxicity.We incubated purified 20 S
proteasomeswith soluble or aggregatedwt or R239CmtGFAPs
in the presence or absence of B-crystallin (at a weight/weight
ratio of GFAP to B-crystallin of 1:2) and then analyzed the
PGPH and chymotrypsin-like proteasome proteolytic activi-
ties. At the GFAP concentration used here (100g/200l), the
soluble R239C GFAP inhibited both PGPH and chymotrypsin
activities, and the pelleted R239C GFAP produced a milder
inhibition (Fig. 5A). The introduction of recombinant B-crys-
tallin attenuated the toxicity of R239C GFAP on proteasome
activities (Fig. 5A).
To validate the protective effects of B-crystallin on protea-
some function in vivo, we increased intracellular B-crystallin
levels using a recombinant adenovirus in U251 cells stably
expressingR239CGFAP. By determining the proteasome activ-
ity using fluorescent substrates, we found that the overexpres-
sion of exogenous B-crystallin attenuated the proteasome
toxicity induced by R239C GFAP (Fig. 5B). As visualized by
immunofluorescence, the overexpressed B-crystallin dis-
persed the GFAP aggregates and shifted them into filamentous
structures (Fig. 5C).
B-Crystallin Changes the Oligomerization State of R239C
GFAP and Promotes GFAP Proteolysis—The R239C mutant
GFAP can assemble into 10-nm filaments, like thewtGFAP (4).
However, a fraction of the GFAP remains in suspension after
centrifuging the reassembled GFAP at 80,000  g, as noted
above. This soluble GFAP fraction was electrophoresed
through a non-SDS, non-reducing 8% PAGE gel and then
immunoblotted to reveal the different GFAP species. The sol-
uble wt GFAP resolved as a mix of monomers (50 kDa) and
higher molecular mass bands, the two main ones representing
dimers and tetramers (Fig. 5D, left panel). In contrast, the
R239C GFAP showed a pronounced shift to higher molecular
mass forms (200–300 kDa, perhaps reflecting 4–6 GFAP
molecules).Whenwe added B-crystallin to the soluble R239C
GFAPand then electrophoresed the protein,we found a pattern
of GFAP monomers and oligomers much more similar to that
of the wtGFAP (Fig. 5D, right panel).We then asked ifB-crys-
tallin would promote more proteolytic degradation of the
R239CGFAP by the 20 S proteasome.When the soluble R239C
GFAP was preincubated with B-crystallin, we found that the
degree of proteolytic breakdown of the GFAP was now similar
to that of the wt GFAP (Fig. 5, E and F). Thus, B-crystallin not
only shifts the monomer-oligomer equilibrium of the R239C
GFAP, but it also allows proteolysis.
DISCUSSION
GFAP Accumulation Inhibits Proteasome Activity—In this
study we investigated how GFAP accumulation in the astro-
cytes of AxD might affect the ubiquitin-proteasome system.
Using fluorogenic peptide assays, we demonstrated decreased
proteasome activities in U251 astrocytoma cells stably express-
ingGFAP and inAxDwhitematter. These results corroborated
our previous findings with a GFP-U proteasome reporter sys-
tem, where overexpressing GFAP impaired proteasome func-
tion (5). Bothwt and R239CGFAP accumulation inhibited pro-
teasome activity, but the R239C GFAP exhibited a greater
inhibitory effect. R239C GFAP tended to aggregate into inclu-
sions (5, 16), which were associated with components of the
proteasome system, such as proteasome 20 S core complexes,
ubiquitinated proteins, and small heat shock proteins, as evi-
denced by immunostaining of cells and of Rosenthal fibers in
AxD brains. Furthermore, we found that ubiquitinated GFAP
protein accumulated in GFAP-overexpressing U251 cells and
in AxD brain tissues and that GFAP further accumulated upon
treatment with MG132 and lactacystin, two proteasome inhib-
itors. These observations point to a role of the ubiquitin-depen-
dent proteasome pathway in the removal of excess GFAP. The
inhibition of proteasome appear, in turn, to aggravate GFAP
accumulation and aggregation, as we observed an increase in
GFAP protein levels and in the percentage of cells bearing
GFAP aggregates (5).
A recent study (17) showed in astrocytoma cells that protea-
some inhibitors down-regulate GFAP gene transcription and
thereby decrease GFAP protein levels. Furthermore, protea-
some inhibition preventsGFAP accumulation in reactive astro-
cytes in a model in which a microdialysis probe through which
an inhibitor was infused was placed in the rat central nervous
system. The trauma of probe placement itself produced
increased GFAP immunostaining, which was prevented by
inhibitor. However, this effect only occurred during the early
increase in GFAP but not after 7 days, suggesting that GFAP
gene expression is initially susceptible to proteasome inhibition
but is no longer susceptible at the higher levels of GFAP protein
that had accumulated by the later stages of astrogliosis. We do
not know if this model applies to the proteasome inhibition in
AxD. For example, inmousemodels of AxD, the levels ofGFAP
mRNA and GFAP protein are both elevated (18).
Proteasomes Bind to Filamentous GFAP—Our data demon-
strated a direct association between filamentous GFAP and the
20 S proteasome complex. The association of proteasomeswith
intermediate filament network of the keratin type has been
reported in PtK1 and HeLa cells (10). In addition, intracellular
localization of proteasomes overlapped with the vimentin net-
work in proliferating human fibroblasts and with desmin inter-
mediate filament in myoblasts of the mouse myogenic cell line
C2.7 (11). A later study also revealed a direct interaction be-
tween proteasomes and the actin network (12). In the present
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FIGURE 5. B-Crystallin restores proteasome proteolytic activity reduced by R239C GFAPs. A, in vitro preincubation of R239C GFAP with B-crys-
tallin (aBC) reversed the inhibitory activity of the R239C GFAP. 20 S only, unexposed proteasomes; MG132, MG 132 control treatment; S, soluble; P,
polymerized. *, p 0.05; **, p 0.001. B, adenoviral introduction of B-crystallin increased proteasome activity in U251 cells expressing R239C GFAP.
Protease activities in cells expressing EGFP-C1 vector (V) are set to 100%. The results are the average from five independent experiments. Adenoviral
infection did not affect the proteasome activity. B-Crystallin expression increased PGPH proteolytic activity in both wt and R239C GFAP-expressing
U251 cells and chymotrypsin-like proteolytic activity in R239C GFAP-expressing cells. *, p  0.05; **, p  0.001. C, morphological changes of GFAP-
expressing U251 cells. U251 cells stably expressing wt or R239C GFAP were infected with B-crystallin-expressing adenovirus, then fixed and processed
for GFP fluorescence.B-Crystallin dispersed the GFAP aggregates inwt-expressing cells and shifted them into filamentous structures. GFAP aggregates
(arrowheads), whereas B-crystallin expression reversed the formation of small GFAP inclusions, shifting the GFAP to large perinuclear aggregates and
filaments. Scale bar, 20 m. D, shown is oligomerization a profile analysis of soluble wt and R239C GFAP preincubated with (right panel) or without
B-crystallin (left panel). The same amounts of soluble wt and R239C GFAP in the absence or the presence of B-crystallin were subjected to non-SDS,
non-reducing, 8% PAGE gel electrophoresis and then immunoblotted for GFAP. E, B-crystallin promotes degradation of the R239C GFAP by the 20 S
proteasome. The same amounts of soluble wt and R239C GFAP (100 g) in the absence or the presence of B-crystallin (200 g) were incubated with
20 S proteasome (100 g). The incubation products were then subjected to 4–12% SDS gradient gel electrophoresis and Western blotting. After
preincubation with B-crystallin, the degree of proteolytic breakdown of the R239C GFAP was similar to that of the wt GFAP. F, the optical density of
degraded GFAP protein bands in Ewas quantitated and plotted to analyze the effects of B-crystallin on GFAP protein degradation. Compared with wt
GFAP, R239C GFAP was less susceptible to proteasome degradation (p 0.05). Preincubation with B-crystallin promoted proteasome degradation of
both wt (p  0.05) and R239C GFAP (p  0.05).
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study we identified an association between proteasomes and
the GFAP intermediate filament network in U251 astrocytoma
cells. This co-localization was particularly visible after treat-
mentwithTritonX-100, which facilitates observation ofGFAP,
as it eliminates most of the soluble proteins. In vitro co-sedi-
mentation experiments further showed a direct interaction
between 20 S proteasome and assembled GFAP filaments. This
was consistent with previous reports on the interaction of pro-
teasomes and reconstituted intermediate filaments of the
vimentin type (12).
Whether this interaction of proteasomes with filamentous
GFAP interferes with proteasome activity is not fully resolved.
For example, we show that a larger proportion of the 20 S sub-
unit associates with the “pellet” fraction of U251 cells than in
control cells (Fig. 1B). This association would deplete protea-
somes from the soluble fraction and, thus, might account for
the loss of proteasome activitymeasured in a soluble fraction in
the cells (Fig. 1A) simply because there are fewer proteasomes
in this soluble fraction.
The in vitro activity assays showed that the filamentous
forms of GFAP did not inhibit proteasome proteolytic activity
asmuch as the soluble forms on aweight/weight basis, although
the filamentous R239C GFAP was more inhibitory than the wt
GFAP.
The Interaction between Proteasomes and Soluble GFAP
Inhibits Proteasome Activity—We demonstrated a direct asso-
ciation between Triton X-100-soluble GFAP and 20 S protea-
some complexes by reciprocal immunoprecipitation from cell
lysates. With this result in mind, we tested the effects of the
soluble fraction of the reassembledGFAP on proteasome activ-
ity in vitro. The soluble fraction consisted of a mix of mono-
meric and oligomeric forms. We use the term “oligomer” to
denote a molecule larger than the monomeric GFAP but
smaller than the polymerized intermediate filament. However,
we know neither the exact structure of these larger soluble
forms nor whether they are normal intermediates in the poly-
merization of R239C GFAP, which will assemble into normal-
appearing 10-nm filaments (4), or abnormal intermediates sep-
arate from the pathway of filament assembly. There was a
marked shift to larger oligomeric forms with the R239C muta-
tion, suggesting that these larger intermediates played a critical
role in the inhibition. Indeed, the greater ability of soluble,
unassembled R239C GFAP compared with assembled R239C
GFAP to inhibit proteasome activity implies that AxD mutant
GFAP inhibits proteasome function primarily through the
accumulation of monomeric and/or oligomeric forms. We
would consider the oligomer forms to be inhibitory given that
decreasing oligomer levels with B-crystallin restored protea-
some proteolytic activity. These observations add to the recent
view in protein misfolding disorders that oligomeric protein
species may be biologically more toxic than larger, aggregated
fibrils (19, 20).
However, we cannot conclude that wt GFAP is innocuous
and can never cause proteasome inhibition. wt GFAP will
inhibit proteasome activity but required higher concentrations
than R239C GFAP. One of the effects of increasing wt GFAP
concentrations would be to increase the concentration of wt
oligomers, butwewould suggest that, because of the differences
in equilibrium, one needs a far higher concentration of wt
GFAP than R239C to reach the same oligomer concentration.
Alternatively, larger amounts of wt GFAPmonomers may sim-
ply provide a competitive inhibition, as proteasome inhibition
might occur at higher rates of substrate degradation, and a
competition between the excess GFAP and other cellular pro-
teins for degradation might occur.
The kinetic analysis showed that the proteolysis of fluoro-
genic substrates was saturable at a constant proteasome con-
centration (Fig. 4). The soluble R239C GFAP produced a
marked inhibition, with a relatively flat activity curve, suggest-
ing a non-competitive component to the inhibition. This could
reflect, for example, R239C oligomer binding to the protea-
some. The oligomer would not be degraded, but its binding
would inhibit the proteolysis of other substrates. The mecha-
nistic model of proteasome degradation proposes that sub-
strates are directed into proteasomes and degraded in the inner
channel of 20 S proteasomes, where the active sites of the cat-
alytic subunits are located. However, only unfoldedmonomeric
peptides are able to slide into the peptide channel, which func-
tions by size exclusion (21). One implication of this model is
that proteins that are in oligomeric assemblies will not be effi-
ciently degraded but will only be degraded after depolymeriza-
tion into a monomeric form. Because monomeric and oligo-
meric forms of GFAPmust exist in equilibrium, any changes to
the protein that shift the equilibrium toward oligomeric forms
will slow proteasomal degradation. One of the dramatic effects
of the R239Cmutation is the shift in molecular mass size in the
soluble GFAP pool toward a larger class of oligomers. We do
not yet knowwhy this equilibrium is so shifted. Presumably the
larger oligomers of the R239CGFAP aremore stable than those
of the wt GFAP, but the structural basis for this stability is
unclear. These observations suggest that further studies of
monomer-oligomer equilibrium with the various GFAPmuta-
tions of Alexander disease are worth pursuing.
Ubiquitin-mediated and Ubiquitin-independent Degrada-
tion of GFAP—The 20 S proteasome particle catalyzes protea-
somal hydrolysis, which can take two forms; ubiquitin-depen-
dent protein degradation, representing the major fraction,
relies on the 26 S proteasomes, and ubiquitin-independent pro-
teolysis of certain unfolded or modified proteins can be carried
out by the single 20 S proteasome (22, 23).Our data suggest that
GFAP can be degraded via both ubiquitin-dependent and
ubiquitin-independent processes. The ubiquitin-independent
GFAP protein degradation has been demonstrated above. We
also found that in cell cultures and AxD brains, GFAPs were
ubiquitinated. Upon proteasome inhibition, there was a further
accumulation of these ubiquitinated species (5). This result was
consistent with our previous observations that defects in pro-
teasomedegradation occurredwhenGFAPwere overexpressed
in the GFP-U proteasome reporter system, suggesting that
overloaded GFAP proteins also damaged the ubiquitin-depen-
dent proteasomal degradation.We also do not exclude the pos-
sibilities that the R239C GFAP may interact with 26 S protea-
some at other sites, such as the proteasome subunit 4 (24) and
the 19 S proteasomal component S6 (25). These sites exert
important roles in mediating the toxicity of -synuclein and
AxDMutant GFAP Accumulation Inhibits Proteasome Function
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parkin (25, 26). However, whether these sites were occupied by
R239C GFAPs still await further study.
The R239C GFAP probably exerted its inhibition by direct
binding to the proteasome. Thus, we found that the protein
degradation of proteasomes preincubated with the R239C
GFAP was inhibited. The binding of R239C GFAP presumably
prevented the fluorogenic peptide from entering the catalytic
compartment of 20 S proteasome complexes either by binding
at the entrance of the peptide channel or by interacting directly
with the inner catalytic compartment of the proteasome in a
manner suggested for the toxicity of amyloid  peptide in
Alzheimer disease (27). Either external or internal binding
could block the entrance of other substrates into the protea-
some chamber or alter the conformation of the active proteo-
lytic site.
B-Crystallin Shifts Monomer-Oligomer Equilibrium of
R239C GFAP and Reinstates Proteasome Degradative Function—
B-Crystallin normalized the equilibrium between oligomers
and monomers to that which resembled wt GFAP. B-Crystal-
lin also mitigated the R239C GFAP-dependent proteasome
inhibition, as measured both by fluorogenic substrate assays
and by the degree of proteolysis of GFAP itself. Thus, a resto-
ration of the normal GFAP size range correlated with a resto-
ration of proteolysis. We presume these two phenomena are
causally related.
The interactions between B-crystallin and GFAP are com-
plex. shsps, B-crystallin, and hsp27 do bind intermediate fila-
ments, both the soluble and the filamentous forms (7). B-Crys-
tallin can inhibit GFAP polymerization (28) and can prevent
GFAP assembly in vitro as well as filament-filament interac-
tions in vitro (7). In cultured astrocytes, B-crystallin overex-
pression can reorganize abnormal
intermediate filament aggregates
into a normal filamentous network
(3) and can spread filament bundles.
In the present study, B-crystallin
overexpression mitigated the pro-
teasome inhibition produced by
the R239C GFAP. Furthermore,
B-crystallin associates with GFAP
aggregates in AxD brains and with
aggregates in cell models produced
by overexpression of R239C GFAP
(this study) and R416W (29).
How does B-crystallin exert its
effects on proteasome dysfunction?
We think the most likely effect is
to depolymerize/disaggregate the
larger GFAP oligomers, presumably
by binding to GFAP and interfering
with GFAP assembly. It seems less
likely that B-crystallin relieves the
proteasome inhibition by prevent-
ing the R239C GFAP from binding
to proteasomes. The interaction
between B-crystallin and GFAP
appears to be more critical than any
possible direct interactions between
B-crystallin and the 20 s proteasome for two reasons. First, we
preincubated B-crystallin with GFAP and found a shift in the
oligomer profile in the absence of proteasomes. Second,
although B-crystallin is reported to interact with the protea-
some subunit, C8/7, its interaction with the full 20 S protea-
some appears much weaker (30). However, we cannot com-
pletely rule out the possibility that a binding of B-crystallin to
proteasomes could relieve the GFAP-induced inhibition,
although it is difficult to formulate such a mechanism.
In cells with accumulated R239C GFAP, the overexpression
of B-crystallin restored proteasomal protein degradation to a
normal level, suggesting that in the living cell B-crystallin
alters the distribution of soluble unassembled GFAP proteins
between monomeric and oligomeric states and helps prevent
an accumulation of toxic oligomers. One might ask, however,
why there is such strong proteasomal inhibition in AxD, given
themarkedly increased levels ofB-crystallin in astrocytes. The
degree of inhibition may be a matter of relative levels of GFAP
and B-crystallin. It is important to consider that although the
large majority of cellular GFAP is cytoskeletal-associated (Tri-
ton X-100 insoluble), there is a soluble pool, and cells express-
ing the R239C GFAP contain a relatively larger soluble pool
than cells expressing wt GFAP (31). A further complication is
that B-crystallin shifts from a largely cytosolic form to a
cytoskeletal-associated form in the presence of GFAP accumu-
lation, probably being bound up by the excess of filaments.
Thus, there is less soluble B-crystallin available in a soluble
pool to bind to GFAP oligomers.
Can Proteasome Inhibition Explain Metabolic Changes Seen
in AxD?—Proteasome inhibition would have a number of con-
sequences for astrocyte function (Fig. 6). It could activate the
FIGURE 6.Proposed consequences of proteasome inhibitionby theAxDGFAPR239Cmutation.Accumu-
lation of GFAP oligomers and aggregates inhibits proteasome proteolytic activity. This inhibition in turn acti-
vates mixed lineage kinase (MLK)/JNK/p38 stress kinase pathways, which up-regulate B-crystallin transcrip-
tion and activate autophagy. BothB-crystallin and autophagy act to decreaseGFAPprotein levels, the former
by inhibiting aggregate formation and reducing inhibitory GFAP oligomer levels and the latter by degrading
GFAP aggregates. Proteasome inhibition also activates ARE-regulated gene expression via increased levels of
Nrf2.MAPK, mitogen-activated protein kinase; ARE, anti-oxidant response element.
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SAPK/JNK stress pathway and compromise the astrocyte abil-
ity to withstand apoptotic stress stimuli (5). Meanwhile, cells
will develop compensatory mechanisms to compensate for the
dysfunction of proteasomes. These mechanisms include the
induction of shsp gene transcription, the accumulation of
shsps, and the induction of autophagy (16). Inhibiting protea-
somes in several cell systems leads to an induction of oxidative
response genes via the Nrf2-regulated transcriptional pathway
(32). Indeed, as predicted, analysis of brain tissues in knock-in
and transgenic mouse models of AxD showed a marked oxida-
tive stress response and the induction of several oxidative stress
response genes (18, 33).
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